small molecule

OPANA ER

OXYMORPHONE HYDROCHLORIDE

Loss of exclusivityNovember 2029latest FDA-listed patent expiry
CompanyENDO OPERATIONS LTD

Drug detail

Brand nameOPANA ER
Active ingredientOXYMORPHONE HYDROCHLORIDE
Strength10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2006
Marketing statusDISCN

Listed patents

PatentExpiresType
8871779November 2029substance
8808737June 2027use U-3085

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OPANA ER patent cliff — loss of exclusivity November 2029 | CliffBio